Pi-RADS 4 Treatment Options: What Are the Next Steps?

A PI-RADS 4 score on a prostate MRI means the radiologist considers it “highly likely” that clinically significant cancer is present in the flagged area. Across multiple studies, roughly half to 60 percent of PI-RADS 4 lesions turn out to be cancer on biopsy, so the finding is serious but far from a guaranteed diagnosis. The next steps almost always begin with a tissue biopsy to confirm or rule out cancer, and the treatment path that follows depends entirely on what that biopsy reveals.

What a PI-RADS 4 Score Actually Tells You

PI-RADS is a five-point scoring system radiologists use when reading multiparametric MRI scans of the prostate. A score of 1 or 2 means cancer is unlikely, 3 is equivocal, and 4 or 5 means cancer is likely or very likely. A large systematic review and meta-analysis found that cancer detection rates for PI-RADS 4 lesions sit around 52 percent on a per-lesion basis and about 59 percent on a per-patient basis, compared to roughly 85 to 89 percent for PI-RADS 5 lesions.¹ A single-center study of 33 patients with PI-RADS 4 scores found a nearly identical positive predictive value of about 51.5 percent.²

In practical terms, this means that if you have a PI-RADS 4 lesion, there is a roughly coin-flip chance it is cancer. That is high enough that virtually every guideline recommends proceeding to biopsy, but it also means a substantial number of people with this score will turn out not to have cancer at all. The number of suspicious lesions can shift those odds: one study found that men with multiple PI-RADS 4 lesions had higher detection rates than those with a single lesion.³

How Consistent Is the Score Between Radiologists?

One concern worth knowing about is that PI-RADS scoring is not perfectly reproducible. When different radiologists read the same MRI, they sometimes assign different scores. An interobserver agreement study found that for PI-RADS 4 or higher, agreement among radiologists improved with the updated version 2.1 of the scoring system in the peripheral zone of the prostate, but remained moderate in the transition zone.⁴ Outside high-volume academic centers, agreement can be lower still, with one study reporting only moderate agreement between readers for PI-RADS 4 and 5 lesions.⁵

This variability matters because a lesion one radiologist calls PI-RADS 4 might be scored as a 3 by another, which could change whether a biopsy is strongly recommended or considered optional. If your score lands right at 4 and you have any doubt, asking whether a second-opinion read by an experienced prostate radiologist would be useful is a reasonable conversation to have with your urologist.

The Biopsy Step

For nearly all men with a PI-RADS 4 lesion, biopsy is the immediate next step. The specific approach matters. MRI-targeted biopsy aims needles directly at the suspicious area identified on the MRI, while systematic biopsy samples tissue from across the prostate in a grid pattern regardless of where the MRI lesion is. Most current practice combines both techniques, and the evidence supports this. One prospective study found that the cancer detection rate using all biopsy methods together was 64 percent in men with PI-RADS 4 lesions, significantly higher than the 23 percent seen in men with PI-RADS 3 scores.⁶

A study examining whether systematic biopsies are still necessary alongside targeted ones in men with PI-RADS 4 or higher lesions found that in about 12 percent of patients, clinically significant cancer was caught only by the systematic samples and would have been missed by targeting alone.⁷ That is a meaningful fraction, which is why most urologists still take both targeted and systematic cores when the MRI shows a PI-RADS 4 finding. Targeted biopsy appears particularly advantageous when the lesion occupies a larger portion of the prostate.⁸

Transperineal Versus Transrectal Biopsy

Biopsies can be done through the skin between the scrotum and rectum (transperineal) or through the rectal wall (transrectal). A systematic review and meta-analysis of randomized controlled trials found that the two routes detect clinically significant cancer at comparable rates when MRI targeting is used.⁹ Another meta-analysis reached similar conclusions, finding no meaningful difference in clinically significant cancer detection between the two routes.¹⁰

The key difference is infection risk. The transperineal route avoids passing a needle through the rectum, which means fewer bacteria are introduced. The first meta-analysis noted significantly fewer infections with transperineal biopsy, including a roughly 65 percent reduction in severe infections.⁹ A pair-matched comparison echoed this pattern: four patients in the transrectal group were hospitalized for urinary tract infections, while none in the transperineal group had severe infectious complications.¹¹ Transperineal biopsy does tend to cause more procedural pain, so your urologist will typically discuss anesthesia options.

When the Biopsy Is Negative

Because roughly half of PI-RADS 4 lesions are not cancer, a negative biopsy is a common outcome. But a negative result in the setting of a suspicious MRI is not always straightforward. An analysis of 76 false-positive PI-RADS 4 biopsies found that the tissue instead showed a mix of normal prostate, chronic inflammation, glandular atrophy, benign nodular hyperplasia, and high-grade prostatic intraepithelial neoplasia (HGPIN).¹² These benign conditions can mimic cancer on MRI because they alter the tissue in ways that change its imaging appearance.

The question of what to do after a negative biopsy with a PI-RADS 4 or 5 lesion is actively debated. A study following men in this situation found that when a repeat MRI was performed, nearly half of the lesions were downgraded to a lower PI-RADS category. However, among the men who went on to have a repeat targeted biopsy, clinically significant cancer was eventually found in 44 percent of them.¹³ That finding suggests that a single negative biopsy does not fully rule out cancer when the MRI is highly suspicious. Most experts recommend either close surveillance with repeat imaging or a repeat biopsy within a defined time frame, rather than assuming all is clear.

If Cancer Is Found on Biopsy

When the biopsy confirms prostate cancer, the treatment decision depends on the cancer’s grade and extent, not the PI-RADS score itself. The PI-RADS number reflects what the MRI looked like; the biopsy grade (often reported as a Grade Group from 1 to 5) tells you how aggressive the cancer cells actually are. That said, higher PI-RADS scores tend to correlate with higher-grade cancer. A study of 322 men who underwent radical prostatectomy found that PI-RADS score was an independent predictor of whether the cancer’s grade would be upgraded from biopsy to the final surgical specimen, which matters when choosing between active surveillance and immediate treatment.¹⁴

The main treatment paths after a positive biopsy in the PI-RADS 4 setting fall into a few broad categories: active surveillance, surgery, radiation, focal therapy, or combinations of these. Which path fits depends on the grade group, the extent of the cancer within the prostate, your PSA level, your age, your overall health, and your own priorities regarding side effects.

Active Surveillance

Active surveillance means monitoring the cancer closely without immediate treatment, with the intent to intervene if it shows signs of progressing. This is increasingly recommended for men with low-grade prostate cancer (Grade Group 1) and is now considered an option even for selected men with favorable intermediate-risk disease (Grade Group 2). A growing body of evidence supports this approach for carefully chosen patients with Grade Group 2 cancer, with studies showing treatment-free survival of about 61 percent at five years and high overall survival, with no distant spread during follow-up in one study.¹⁵

The PI-RADS score plays a role in surveillance strategy. A study specifically looking at men on active surveillance with PI-RADS 4 index lesions found that 18 percent progressed to Grade Group 3 or higher, with a median time to progression of about 74 months (roughly six years).¹⁶ That progression rate means active surveillance can be a viable choice for men with lower-grade biopsies even in the presence of a PI-RADS 4 lesion, but it underscores why the surveillance protocol needs to be followed carefully, with regular PSA checks, repeat MRIs, and periodic re-biopsies. A cost-effectiveness analysis found that annual MRI with biopsy triggered at PI-RADS 4 or greater was the most cost-effective surveillance strategy.¹⁷

Surgery

Radical prostatectomy removes the entire prostate gland. It is one of the most common treatments for localized prostate cancer, and robot-assisted surgery has become the predominant approach at most centers. For PI-RADS 4 and 5 lesions specifically, one concern is the risk of positive surgical margins, meaning cancer cells are found at the cut edge of the removed tissue. A study of robot-assisted laparoscopic prostatectomy found that PI-RADS 4 was associated with roughly a 3.5-fold increased risk of positive margins, and PI-RADS 5 with about a six-fold increased risk, compared to lower scores.¹⁸ A positive margin does not necessarily mean the cancer will return, but it can prompt discussions about follow-up radiation.

The side effects of surgery center on urinary control and sexual function. A ten-year comparison of treatment complications for intermediate-risk prostate cancer found that the prevalence of erectile dysfunction was about 24 percent for men who had surgery, compared to roughly 7 percent for external beam radiation and 8 percent for brachytherapy. Severe urinary complications were about 10 percent for surgery, 12.5 percent for external beam radiation, and around 5 percent for brachytherapy.¹⁹ These numbers help illustrate why treatment selection is deeply personal; it depends on which potential side effects you find most acceptable.

Radiation Therapy

Radiation can be delivered externally (external beam radiation therapy, or EBRT) or internally by placing radioactive seeds directly into the prostate (brachytherapy). Both are well-established options for localized prostate cancer. A growing variation is stereotactic body radiation therapy (SBRT), which delivers higher doses per session over far fewer visits. A comparison of conventional fractionation versus SBRT found that PSA levels dropped faster and lower over two to three years after SBRT than after conventional radiation, suggesting comparable or potentially stronger tumor control in the medium term.²⁰

Radiation’s side-effect profile differs from surgery. Rectal complications tend to be slightly more common with external beam radiation, while erectile dysfunction rates at ten years are substantially lower than after surgery, as noted above.¹⁹ Brachytherapy in particular had the lowest rate of severe urinary complications in that comparison.

Combining Radiation with Hormone Therapy

For men with intermediate or high-risk prostate cancer, radiation is often paired with androgen deprivation therapy (ADT), which suppresses testosterone to slow cancer growth. Evidence shows that ADT has both an independent anti-cancer effect and a synergistic effect with radiation, essentially making cancer cells more vulnerable to radiation damage by interfering with their ability to repair DNA.²¹

Not every man benefits equally from adding hormones. A study separating patients by risk found that younger men (70 or younger) with intermediate-risk disease who received radiation alone had significantly higher rates of biochemical relapse than those who also received ADT. At six years of follow-up, biochemical relapse-free survival was about 82 percent for radiation alone versus 94 percent with the combination.²² ADT has its own side effects, including fatigue, hot flashes, loss of libido, and metabolic changes, so the decision to add it depends on whether the cancer’s risk profile justifies those trade-offs.

Focal Therapy

Focal therapy treats just the cancerous area of the prostate rather than the whole gland, aiming to control the cancer while preserving more urinary and sexual function. The most established modalities are high-intensity focused ultrasound (HIFU) and cryotherapy, though newer energy sources are under investigation. Reviews of the evidence describe favorable short-term cancer control and preserved functional outcomes across different focal therapy techniques.²³ Rates of urinary continence and sexual function preservation tend to be high, and cancer control in well-selected patients has been described as comparable to radical treatments.²⁴

One concern with focal therapy is whether the location of the tumor affects outcomes. A study examining both HIFU and cryotherapy found that the position of the cancer within the prostate, including lesions near the apex, did not significantly affect failure rates, suggesting these techniques can be applied to a range of tumor locations.²⁵ Focal therapy is generally offered to men with low-risk or favorable intermediate-risk disease where the cancer is well-defined on MRI. It is less established for high-risk disease, and long-term data are still accumulating compared to the decades of follow-up available for surgery and radiation.

Staging and What Drives the Treatment Choice

When biopsy confirms cancer in a PI-RADS 4 setting, the next question is whether it has stayed within the prostate or begun to extend beyond it. The MRI that generated the PI-RADS score already provides some staging information, but for higher-risk cases, additional imaging may be useful. A study combining multiparametric MRI with PSMA-PET/CT scanning found that the combination correctly predicted the local stage (T-stage) in 87 percent of patients with PI-RADS 4 and 5 lesions.²⁶ Accurate staging directly affects whether whole-gland treatment is needed, whether lymph nodes should be targeted, and whether hormone therapy should be added.

Treatment decisions for prostate cancer are rarely made by a single doctor. A multidisciplinary approach involving urologists, radiation oncologists, medical oncologists, and radiologists is considered the standard of care for good reason. The factors feeding into the decision span the biological aggressiveness of the tumor, the patient’s overall health, their life expectancy, and their personal preferences about quality of life.²⁷ A prospective study tracking treatment decisions after multidisciplinary clinic visits found that patients preferred an active role in the process and rated the doctors at the clinic as their most helpful source of information. Treatment choices broke down predictably by risk: men with low and intermediate-risk cancer most often chose surgery or radiation, while men with high-risk cancer were more likely to choose radiation combined with hormone therapy.²⁸

MRI-Guided Biopsy and Screening Economics

For men whose PI-RADS 4 score arose in the context of PSA-based screening, the MRI-guided pathway has broader cost implications. A cost-effectiveness analysis comparing MRI-guided biopsy strategies with standard biopsy across various PSA ranges found that the MRI-plus-targeted-biopsy approach was cost-effective at conventional thresholds across all three PSA strata tested (2.5 to 4.0, 4.1 to 10.0, and above 10.0 ng/mL).²⁹ A large randomized clinical trial also compared a biomarker-based screening approach against an MRI-enhanced strategy and found that MRI-based screening detected clinically significant cancers at a comparable rate while prompting fewer biopsies and catching fewer low-risk cancers that might otherwise lead to overtreatment.³⁰ This is relevant if you are wondering whether the MRI step that produced your PI-RADS 4 score was worthwhile: the evidence strongly suggests it is a more precise way to identify men who actually need a biopsy, reducing unnecessary procedures while catching the cancers that matter.

1
Prostate Cancer and Prostatic Diseases. Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level
2
PubMed Central. Positive Predictive Value of High-Grade Prostate Imaging and Reporting Data System V2.1 Magnetic Resonance Imaging Findings for Prostate Cancer
3
Journal of Clinical Oncology. The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men
4
PubMed. PI-RADS Versions 2 and 2.1: Interobserver Agreement and Diagnostic Performance in Peripheral and Transition Zone Lesions Among Six Radiologists
5
PubMed Central. Performance and Inter-observer Variability of Prostate MRI (PI-RADS version 2) Outside High-volume Centres
6
JAMA Surgery. Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive
7
The French Journal of Urology. PIRADS ≥ 4 MRI lesion: Is performing systematic biopsies still essential for detecting clinically significant prostate cancer?
8
PubMed Central. Comparison of MRI/US Fusion Targeted Biopsy and Systematic Biopsy in Biopsy-Naïve Prostate Patients with Elevated Prostate-Specific Antigen
9
PubMed Central. Transperineal Versus Transrectal Prostate Biopsy: A Systematic Review and Meta-analysis of Randomized Controlled Trials Across Settings With and Without Magnetic Resonance Imaging Targeting
10
PubMed. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Prostate Biopsy: A Systematic Review and Meta-analysis of Prospective Studies
11
Scientific Reports. Transperineal vs transrectal magnetic resonance and ultrasound image fusion prostate biopsy: a pair-matched comparison
12
Journal of Clinical Oncology. Analysis of false-positive biopsy results of PIRADS 4 lesions in multiparametric magnetic resonance imaging of the prostate
13
Scientific Reports. Follow-up of men with a PI-RADS 4/5 lesion after negative MRI/Ultrasound fusion biopsy
14
PubMed Central. Prediction of prostate cancer Gleason score upgrading from biopsy to radical prostatectomy using pre-biopsy multiparametric MRI PIRADS scoring system
15
Prostate International. Patients with high-risk features on active surveillance for prostate cancer
16
PubMed Central. PI-RADS Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance
17
PubMed Central. Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness
18
PubMed Central. Analysis of risk factors for positive margins in robot-assisted laparoscopic radical prostatectomy with Retzius-sparing (RS-RARP)
19
PubMed. Ten-year treatment complication outcomes of radical prostatectomy vs external beam radiation vs brachytherapy for 1503 patients with intermediate risk prostate cancer
20
PubMed Central. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir
21
PubMed Central. Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
22
PubMed Central. Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
23
PubMed. Oncologic and functional outcomes of novel focal therapy methods for low-risk to intermediate-risk prostate cancer
24
Société Internationale d’Urologie Journal. SIU-ICUD: Principles and Outcomes of Focal Therapy in Localized Prostate Cancer
25
PubMed. Association between Lesion Location and Oncologic Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy
26
PubMed Central. Prediction of T staging in PI-RADS 4–5 prostate cancer by combination of multiparametric MRI and 68 Ga-PSMA-11 PET/CT
27
PubMed Central. Multi-disciplinary and shared decision-making approach in the management of organ-confined prostate cancer
28
PubMed. A prospective cohort study of treatment decision-making for prostate cancer following participation in a multidisciplinary clinic
29
PubMed Central. Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results
30
JAMA Network Open. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial